ZURICH, April 21 (Reuters) - Actelion, Europe's biggest biotech firm, on Tuesday upped its full-year guidance after reporting first-quarter earnings that exceeded analysts' estimates.
The Swiss drugs company reported a 10 percent year-on-year rise in first-quarter product sales to 515 million Swiss francs ($538.42 million), generating net income of 159 million francs, up 25 percent on the same period last year.
11:20 PE firm Warburg buys $121 million stake in Indian cinema operator PVR9
06:13 Pound quivers near three-month low, stocks weak before May's Brexit stance speech17
19:08 U.S. indicts three Takata executives, fines company $1 billion in faulty air bag scandal16
12:02 Bank of America tops earnings forecast, predicts 'significant increase' in net interest income20